Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Y. Huang



Author of

  • +

    P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Biology, Pathology, and Molecular Testing
    • Presentations: 1
    • +

      P3.04-082 - Activation of JAK1 Confers Poor Prognosis in Chinese Patients with Lung Adenocarcinoma (ID 757)

      09:30 - 09:30  |  Author(s): Y. Huang

      • Abstract

      Background:
      Janus kinase 1 (JAK1) has been reported to activate the JAK/STAT cascade in non-small cell lung cancers (NSCLC), among which most lung adenocarcinoma (ADCC) is associated with somatic epidermal growth factor receptor (EGFR) tyrosine kinase mutations. STAT3 is considered to be one of both JAK1 and EGFR downstream pathways promoting oncogenesis. However, the association between JAK1 activation, EGFR mutations and their prognostic value on NSCLC remains unclear. This study explored relations between the activated form, p-JAK1 and prognosis in patients with NSCLC and EGFR mutations status with ADCC subjects.

      Methods:
      a cohort of 142 resected primary NSCLC cases including 74 ADCC and 68 squamous carcinoma (SqCC) were collected and analyzed, p-JAK1 expression was determined by immunohistolchemical (IHC) assay. EGFR FISH status was analyzed in 74 ADCC subjects. The prognostic significances of p-JAK1 and EGFR expression status were evaluated with univariate and multivariate survival analysis.

      Results:
      Compared with normal lung tissues, p-JAK1 expression level significantly increased in NSCLC (P=0.000). Positive p-JAK1 expression indicated poor prognosis in NSCLC, especially in early stage subjects (T1+T2, N0+N1, stage I + stage II) (All P<0.05). (P=0.001).Figure 1 p-JAK1 is an independent predictor for poor prognosis (P=0.022). Further analysis showed that significance existed only in ADCC cases but not in SqCC. Survival time for p-JAK1(+)/EGFR(+) subjects was drastically shortened than the other 3 combinations Figure 2





      Conclusion:
      Our results provided clinical evidence that activation of JAK1 is an independent prognostic factor in early stage NSCLC, especially in ADCC. EGFR and p-JAK1 combination could be a new target for selecting individual therapy strategies and predicting therapeutic effect for NSCLC.